Overview
Explore compounds researched for muscle retention, anabolic signaling, training recovery, and performance-oriented GH-axis support.
12 of 46 published compounds
$600.00
Muscle Growth & Strength, GH Axis Optimization
muscle gain, strength support, training output, lean-mass focus
Goal hub next step
Build a muscle & performance research path.
Use the quiz before choosing a compound, vendor, or PDF so the route reflects your goal, risk tolerance, and monitoring comfort.
Best options to research first
Ranked by evidence first, then risk. A research starting point, not a clinical recommendation.
Tesamorelin
FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.
subcutaneous
Clinical endpoints assessed at 26 weeks in pivotal studies.
$600.00
3 tracked
Sermorelin
GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.
subcutaneous
GH secretion changes occur acutely; body composition endpoints are months-horizon.
$480.00
1 tracked
CJC-1295
Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.
subcutaneous
Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose.
$143.98
3 tracked
GHRP-2
GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.
intravenous, subcutaneous
Acute hormone response within minutes to hours in stimulation tests.
0 tracked
GHRP-6
GH secretagogue with phase I PK data in humans. FDA has flagged compounding safety concerns.
intravenous, subcutaneous
Acute GH response after IV dosing; PK shows hours-scale elimination.
€35.76
1 tracked
Ipamorelin
Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.
subcutaneous, intravenous
GH pulse effects are acute; body composition claims are long-horizon and not well-established.
$180.00
3 tracked
Lower-risk options
Higher-risk options
Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses.
Endocrine spillover (ACTH, cortisol, prolactin); glucose metabolism concerns.
Immunogenicity/impurity concerns (FDA); cortisol effects; decreased insulin sensitivity; glucose metabolism risk.
Immunogenicity risk (FDA); impurity concerns with unnatural amino acids; glucose/cortisol axis concerns.
Trusted vendors for performance and GH-axis research
These vendors currently carry compounds in this goal category. Hub is the trust layer; outbound clicks happen after comparison.
XL Peptides
5 relevant compounds in hub
testing reports on product page
third-party testing reports linked on product page
UK, Europe, and rest of world via vendor shipping options
affiliate: direct product page
Ignite Peptides
4 relevant compounds in hub
COA with order / verify current product report
third-party testing and COA documentation claimed by vendor; verify product-specific report
U.S. domestic territories only
affiliate: direct product page
Amino Club
4 relevant compounds in hub
product page COA viewer
third-party purity testing; product-level COA on page
US/ROW (verify current policy)
affiliate: public program
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.